New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
06:05 EDTJAZZJazz Pharmaceuticals price target raised to $195 from $132 at Citigroup
Citigroup raised its price target for Jazz Pharmaceuticals shares to $195 following the company's Q4 results and keeps a Buy rating on the stock. Citi says the CFO departure likely eases some of the takeout speculation around the stock, but it points out Jazz's 2014 guidance points to solid top and bottom line growth.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use